AstraZeneca PLC AZN
Open calendar →AstraZeneca PLC Ordinary Shares · Company · NYSE
USD closing-price chart (daily close from yfinance · Last year)
USD 140.96 → 169.73 · 20.4%
Numbered dotted lines mark the filtered filings under Announcement Events below.
Price & SEC Filing History 22 Jul 2025 — 23 Jul 2026 (Last year)
Daily NYSE prices are sourced from yfinance. Yellow highlighting marks an intraday rise or a gap up between adjacent trading sessions. SEC acceptance times are converted to US Eastern time: pre-market filings appear below that day’s OHLCV row; filings accepted after the 09:30 ET open appear above it. The SEC does not publish an exact first-public-availability timestamp, so acceptance time is the best available proxy.
Date
Open
High
Low
Close
Volume
No data yet
94 · 6-K
Pre-market · 02:01 ET
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER ↗
170.6400
170.8900
168.4650
169.7300
1,560,207
165.3500
169.4300
164.8200
169.3400
1,986,000
168.4600
168.6500
164.0600
164.5200
2,552,900
Weekend
Weekend
168.1500
170.3100
167.1500
168.9000
1,981,300
167.9700
170.3700
167.2500
169.2900
3,018,300
166.2200
169.5800
166.2100
168.3700
2,938,200
167.3600
168.1000
164.4500
164.5000
3,605,500
93 · 6-K
Pre-market · 06:37 ET
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR ↗
168.7500
170.4700
168.1100
169.4700
4,666,100
Weekend
Weekend
175.4900
175.8800
171.4200
171.6100
3,596,900
173.4500
180.2100
172.7600
178.4900
6,649,000
92 · 6-K
Pre-market · 06:17 ET
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL ↗
189.9500
191.4800
188.6700
189.2800
1,967,800
192.9800
193.7900
191.6000
193.1200
2,130,000
190.2000
190.2400
186.2400
190.1600
1,872,000
Weekend
Weekend
No trading
189.5200
196.4100
189.1700
195.1500
2,379,500
91 · 6-K
After market open · 10:10 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
90 · 6-K
After market open · 10:06 ET
TOTAL VOTING RIGHTS ↗
187.0700
187.6500
183.4900
183.8600
2,115,500
190.3100
190.4600
186.1600
189.6200
2,598,700
189.2500
191.1300
188.4500
190.9500
1,644,300
89 · 6-K
Pre-market · 06:45 ET
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS ↗
88 · 6-K
Pre-market · 06:05 ET
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC ↗
Weekend
Weekend
184.2800
189.5700
184.2800
188.4100
3,235,300
184.8200
186.5800
184.5500
185.6800
1,826,200
183.4000
184.6100
182.1900
183.0200
2,377,700
179.8100
181.1500
179.2800
181.0200
1,503,700
175.2900
177.4300
175.1100
176.4300
1,489,600
Weekend
Weekend
No trading
177.6700
177.8000
173.6600
174.9300
1,667,000
178.7000
180.4400
177.6500
177.8900
1,868,700
178.3300
179.1200
176.6400
178.7100
1,895,800
179.1600
179.2200
176.5500
177.2700
1,328,700
87 · 6-K
Pre-market · 06:52 ET
TRUQAP APPROVED IN US FOR PROSTATE CANCER ↗
Weekend
Weekend
182.5300
182.7000
178.5900
178.7500
2,394,100
181.3600
183.6700
180.3900
182.2800
1,749,400
180.9400
181.7200
177.8800
178.9600
2,129,600
181.7300
183.8100
181.1600
183.4300
1,963,700
184.1600
185.3100
181.3600
181.5500
2,040,000
Weekend
Weekend
184.0200
186.1200
184.0200
185.9500
2,346,100
180.5800
183.3700
180.2400
181.8000
2,030,300
174.6000
177.5600
174.6000
176.2800
2,397,000
179.1000
179.5600
176.0300
177.4500
2,035,100
86 · 6-K
After market open · 10:10 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
85 · 6-K
After market open · 10:06 ET
TOTAL VOTING RIGHTS ↗
182.7200
183.2300
179.6200
179.7100
2,892,500
Weekend
Weekend
185.9900
187.1000
184.6500
185.6700
1,499,100
84 · 6-K
Pre-market · 06:43 ET
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER ↗
183.8000
186.4600
183.3600
185.3300
2,059,500
187.4300
188.7200
185.3800
185.6500
2,121,600
83 · 6-K
Pre-market · 06:04 ET
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED ↗
188.2600
188.6100
186.7400
187.1900
1,411,800
82 · 6-K
Pre-market · 07:17 ET
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC ↗
81 · 6-K
Pre-market · 07:09 ET
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS ↗
80 · 6-K
Pre-market · 07:02 ET
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU ↗
No trading
Weekend
Weekend
188.2200
189.0800
186.4500
187.0300
2,120,800
185.8400
191.5000
184.9800
189.7500
2,192,700
186.6900
188.3100
185.7300
187.4600
1,803,500
184.7000
186.3600
184.1900
184.6400
1,616,800
79 · 6-K
After market open · 10:15 ET
DIRECTOR/PDMR SHAREHOLDING ↗
78 · 6-K
After market open · 09:42 ET
BAXFENDY APPROVED IN THE US FOR HYPERTENSION ↗
77 · 6-K
After market open · 09:36 ET
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS ↗
183.4300
184.7400
182.6700
183.9200
1,225,200
Weekend
Weekend
183.2500
183.4400
180.5500
181.5800
1,379,300
186.6900
186.7000
184.7000
184.9600
1,027,700
76 · 6-K
Pre-market · 07:25 ET
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER ↗
183.3600
187.7800
183.3300
187.7200
1,733,000
183.0100
185.8200
182.7000
184.5400
1,595,900
183.7900
185.8100
181.7300
181.8600
2,106,700
Weekend
Weekend
182.7100
183.5500
181.5800
182.8500
1,910,400
184.3700
184.3700
181.0300
182.5200
2,749,500
184.5300
185.6100
183.5500
184.9200
1,953,700
181.4800
181.9800
180.0000
181.2400
2,459,800
184.3600
185.1900
182.8000
183.4600
1,170,100
Weekend
Weekend
75 · 6-K
After market open · 10:23 ET
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES ↗
185.4500
187.1800
184.0100
184.7400
1,793,600
74 · 6-K
Pre-market · 08:45 ET
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER ↗
73 · 6-K
Pre-market · 08:40 ET
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER ↗
188.4700
190.0000
186.8700
187.3700
2,797,300
183.9300
187.0000
181.7300
185.2000
4,442,800
72 · 6-K
Pre-market · 07:23 ET
1ST QUARTER RESULTS ↗
186.9100
187.9800
185.4100
186.6800
2,837,100
71 · 6-K
Pre-market · 07:31 ET
BREZTRI APPROVED IN THE US FOR ASTHMA ↗
188.9100
190.5900
187.2000
187.5100
2,102,000
70 · 6-K
Pre-market · 06:29 ET
SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US ↗
Weekend
Weekend
189.1500
189.9400
187.5600
189.7500
2,388,300
195.2100
196.6400
191.8100
192.3000
2,179,300
69 · 6-K
Pre-market · 06:10 ET
DIRECTORATE CHANGE ↗
196.5500
196.6500
194.8000
194.8100
1,578,700
198.8500
198.9900
195.7700
195.7800
2,130,700
68 · 6-K
Pre-market · 06:19 ET
I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT ↗
202.8100
203.3700
200.6700
200.6900
1,104,500
67 · 6-K
Pre-market · 07:03 ET
THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD ↗
Weekend
Weekend
202.8100
205.3000
202.5500
204.8000
1,241,300
201.4400
201.8000
199.9900
200.4700
1,414,400
204.2000
204.3900
199.5000
201.2100
1,657,800
202.5500
204.7300
202.0700
204.3800
2,257,500
202.4800
203.1800
200.7000
202.2400
1,724,300
Weekend
Weekend
207.3000
207.3000
203.8200
204.0300
1,565,700
66 · 6-K
After market open · 13:01 ET
RESULT OF AGM ↗
202.6400
206.5000
201.9700
204.9900
1,239,200
205.4500
206.7300
203.6600
204.2700
2,282,900
198.7100
202.0000
196.9500
200.8100
2,450,800
204.7500
204.7500
202.7300
202.8300
1,554,700
Weekend
Weekend
No trading
199.7800
204.3400
199.2300
203.4900
2,049,300
65 · 6-K
Pre-market · 09:27 ET
IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER ↗
64 · 6-K
After market open · 10:30 ET
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES ↗
198.8900
201.7400
198.7200
200.7300
2,158,600
194.8500
197.2700
193.5500
197.2200
2,759,600
63 · 6-K
Pre-market · 07:48 ET
EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS ↗
193.8300
194.6400
192.6100
193.8800
2,113,900
Weekend
Weekend
190.8800
192.9700
187.9500
188.4200
2,762,900
62 · 6-K
Pre-market · 08:04 ET
TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS ↗
185.0800
186.8100
182.7900
183.4000
1,850,300
187.6700
188.7200
186.4400
187.1400
1,484,000
182.6300
186.2200
182.3900
185.7800
1,596,200
183.8600
186.7800
183.7600
184.0700
2,009,400
Weekend
Weekend
188.1400
188.4000
182.6200
183.6000
2,068,000
61 · 6-K
Pre-market · 07:59 ET
NOTIFICATION OF ADMISSION OF SHARES ↗
186.7300
189.7900
186.3300
188.9300
1,469,900
190.6700
190.7300
187.5600
188.4200
1,174,400
193.9600
193.9600
190.9500
191.2900
1,455,600
190.8100
192.5100
190.5400
192.0100
1,828,800
60 · 6-K
Pre-market · 08:45 ET
IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER ↗
Weekend
Weekend
192.6400
193.6500
189.4300
189.9000
1,429,000
193.9100
193.9200
190.9600
192.5000
2,154,800
194.2200
194.8300
192.3100
193.3100
1,416,800
196.7200
198.0900
194.8100
194.9900
1,658,200
59 · 6-K
Pre-market · 08:07 ET
NOTICE OF AGM ↗
58 · 6-K
Pre-market · 07:37 ET
FORM 6-K ↗
190.3300
195.7900
189.3500
194.9500
1,875,000
Weekend
Weekend
194.0100
194.8300
192.7600
194.2200
1,473,800
57 · 6-K
Pre-market · 08:11 ET
DIRECTOR/PDMR SHAREHOLDING ↗
56 · 6-K
Pre-market · 07:50 ET
DIRECTOR/PDMR SHAREHOLDING ↗
55 · 6-K
Pre-market · 07:43 ET
DIRECTOR/PDMR SHAREHOLDING ↗
199.4000
199.5200
195.2600
197.5200
2,648,600
203.2200
203.2900
200.5500
201.5300
2,911,100
200.0000
201.9900
197.1000
201.7600
2,733,100
54 · 6-K
After market open · 12:00 ET
TOTAL VOTING RIGHTS ↗
53 · 6-K
After-hours · 16:05 ET
FORM 6-K ↗
205.6400
206.3000
203.3400
203.7300
1,718,800
Weekend
Weekend
52 · 424B2
After-hours · 16:05 ET
424B2 ↗
207.2700
209.9300
206.9500
208.4500
1,996,300
204.9800
205.1600
202.6400
203.9800
2,250,400
51 · 6-K
Pre-market · 08:59 ET
ASTRAZENECA PRICES A $2BN BOND OFFERING ↗
50 · 6-K
After market open · 10:40 ET
FILING OF FORM 20-F WITH SEC ↗
206.7500
207.5500
205.3000
205.7900
1,434,800
49 · 424B2
Pre-market · 08:30 ET
424B2 ↗
46 · 20-F
After-hours · 16:17 ET
20-F ↗
45 · 6-K
After-hours · 16:06 ET
FORM 6-K ↗
208.9900
209.3500
206.4900
206.6100
1,710,800
48 · 6-K
Pre-market · 06:51 ET
ANNUAL FINANCIAL REPORT ↗
47 · 6-K
Pre-market · 06:45 ET
DIRECTORATE CHANGE ↗
204.6000
207.3400
204.2600
204.9400
1,815,400
Weekend
Weekend
206.6000
207.6900
204.0500
204.2000
1,592,700
44 · 6-K
Pre-market · 06:57 ET
FIXED-DURATION CALQUENCE COMBO APPROVED IN US ↗
208.7500
208.9500
205.7200
208.6200
2,036,900
212.6600
212.7100
207.5200
208.6700
2,604,100
208.1000
211.2700
207.8500
209.4800
2,287,700
No trading
Weekend
Weekend
205.6400
206.7100
204.0900
205.5500
2,504,800
202.5200
205.8600
202.1000
204.5200
2,723,800
200.0800
204.9200
199.1900
204.7600
3,483,900
43 · 6-K
After market open · 11:55 ET
FINAL RESULTS ↗
194.0200
195.9000
190.6000
193.4000
2,726,400
191.8000
192.7600
187.0600
188.0100
3,030,400
Weekend
Weekend
190.4600
193.9700
188.4900
193.0300
3,117,300
187.0700
190.6700
186.5800
187.1600
3,380,500
189.0600
190.7000
186.3200
187.4500
3,889,200
187.6100
190.7200
183.6300
184.3200
2,659,700
42 · 6-K
Pre-market · 07:01 ET
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION ↗
41 · 6-K
After market open · 13:26 ET
TOTAL VOTING RIGHTS ↗
190.4400
192.7900
186.1800
188.4100
3,228,800
40 · 6-K
Pre-market · 07:51 ET
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER ↗
39 · 6-K
Pre-market · 07:25 ET
ASTRAZENECA BEGINS TRADING ON NYSE ↗
Weekend
Weekend
186.0600
187.0200
184.9200
185.5400
2,777,500
38 · 6-K
Pre-market · 06:19 ET
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC ↗
186.7400
187.0600
185.1400
185.1800
3,237,350
37 · 6-K
Pre-market · 08:08 ET
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 ↗
186.3400
187.6800
185.8000
186.4400
4,117,150
189.3000
192.3600
189.3000
191.2000
3,526,350
186.2800
189.1800
186.1600
188.4600
3,054,100
Weekend
Weekend
184.1200
185.9800
182.8800
185.9000
2,161,400
180.9000
183.5800
180.3400
183.3800
3,072,600
179.3600
181.5800
178.0800
181.0800
4,558,000
180.2800
182.2400
178.3400
179.8800
5,568,650
36 · 6-K
Pre-market · 07:18 ET
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE ↗
No trading
Weekend
Weekend
188.9400
189.3600
187.0200
188.7800
27,525,250
190.6000
190.7200
186.8200
187.9800
4,573,200
192.0400
192.8600
190.7400
192.6800
3,854,650
188.2800
189.0800
185.5600
189.0200
4,018,600
190.2800
190.3600
186.8200
187.2600
5,377,550
Weekend
Weekend
190.4800
191.8800
189.0800
189.3000
3,038,700
190.3600
191.9000
186.4400
188.0200
2,808,100
35 · 6-K
Pre-market · 06:04 ET
AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON ↗
189.6200
193.0200
188.2400
190.3200
3,307,450
184.9800
190.5400
184.9200
189.9200
3,162,450
182.3400
182.7600
179.0600
182.4400
2,954,200
Weekend
Weekend
34 · 6-K
After market open · 12:24 ET
TOTAL VOTING RIGHTS ↗
184.7800
184.9000
182.3400
183.1400
1,781,600
No trading
184.5000
184.9600
183.8400
183.8600
1,048,650
185.3200
185.7600
184.7200
185.0200
865,100
184.6600
185.7800
184.6600
185.0400
1,185,900
Weekend
Weekend
185.0600
185.8200
184.3600
185.8000
834,700
No trading
184.6400
185.2200
184.0200
184.9000
592,350
185.0400
186.2000
183.8800
184.2800
1,772,200
181.6200
183.7200
181.2600
183.1000
2,324,500
33 · 6-K
Pre-market · 07:47 ET
DIRECTOR/PDMR SHAREHOLDING ↗
32 · 6-K
Pre-market · 07:18 ET
ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC ↗
31 · 6-K
Pre-market · 07:02 ET
UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB ↗
Weekend
Weekend
180.8600
183.7400
180.7200
182.7200
4,187,150
30 · 6-K
Pre-market · 08:35 ET
DIRECTOR/PDMR SHAREHOLDING ↗
180.5800
182.3400
180.3800
181.2200
3,414,250
182.1800
182.5000
179.7000
179.7200
2,987,750
181.7400
183.1600
180.3800
182.7000
2,257,450
29 · 6-K
Pre-market · 06:42 ET
SUBCUTANEOUS SAPHNELO APPROVED IN EU ↗
28 · 6-K
Pre-market · 06:19 ET
ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC ↗
180.7400
183.5800
180.2400
183.1200
3,510,200
Weekend
Weekend
178.8000
179.9200
178.5600
179.6600
2,688,650
181.2400
183.0400
180.4000
180.5800
3,313,950
182.3600
183.3200
179.4000
183.0200
3,059,950
182.3600
182.9000
179.5600
179.6400
2,363,900
180.7400
182.7400
179.3400
182.5600
3,527,750
Weekend
Weekend
181.3800
182.3600
180.1400
180.3600
2,716,450
27 · 6-K
After market open · 13:48 ET
HOLDING(S) IN COMPANY ↗
181.3000
181.7400
179.5400
180.0600
2,625,450
181.3800
182.5600
181.0400
181.7000
3,418,500
181.8200
182.1600
180.2800
180.3400
3,252,350
26 · 6-K
After market open · 11:47 ET
BLOCK LISTING INTERIM REVIEW ↗
25 · 6-K
After market open · 11:40 ET
TOTAL VOTING RIGHTS ↗
185.8800
185.9600
180.8600
181.0400
3,183,300
Weekend
Weekend
185.1400
185.6600
184.1000
185.4400
1,874,000
No trading
186.0000
188.0400
185.6800
186.6400
2,328,000
24 · 6-K
Pre-market · 06:27 ET
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER ↗
184.8800
186.8200
184.4000
186.4800
2,712,750
181.2200
183.6600
181.2200
183.0400
2,863,100
23 · 6-K
Pre-market · 06:54 ET
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND ↗
Weekend
Weekend
178.6800
183.8200
178.6800
182.0000
3,701,150
179.7000
180.0200
176.8200
177.3600
2,931,500
22 · 6-K
Pre-market · 08:31 ET
KOSELUGO (SELUMETINIB) APPROVED IN THE US ↗
179.1200
180.1400
177.1800
177.9800
3,219,300
178.0600
179.4200
176.8800
179.1000
3,178,950
21 · 6-K
After market open · 12:52 ET
HOLDING(S) IN COMPANY ↗
178.6600
180.5400
178.2400
178.8000
1,907,050
Weekend
Weekend
20 · 6-K
After market open · 10:12 ET
DIRECTOR/PDMR SHAREHOLDING ↗
177.0400
178.7400
176.5600
178.2000
2,045,200
175.7800
178.8600
175.2400
177.2200
2,257,200
176.5400
177.8000
174.4600
175.3600
2,615,800
176.3800
178.6400
176.0000
178.1800
2,481,600
19 · 6-K
After market open · 12:15 ET
DIRECTOR/PDMR SHAREHOLDING ↗
172.4800
175.0600
171.7000
174.9600
3,135,700
Weekend
Weekend
169.1000
170.3000
168.4400
169.1600
2,052,900
168.6200
170.0400
166.7400
167.5400
3,471,050
18 · 6-K
Pre-market · 07:36 ET
9M AND Q3 2025 RESULTS ↗
162.7600
164.1800
162.0400
162.3000
2,724,400
161.3000
164.2200
160.9600
164.0600
2,336,600
17 · 6-K
After market open · 13:31 ET
RESULT OF GENERAL MEETING ↗
16 · 6-K
After market open · 13:22 ET
TOTAL VOTING RIGHTS ↗
15 · 6-K
After market open · 12:36 ET
FORM 6-K ↗
163.9600
164.8000
162.1000
163.4400
1,448,050
Weekend
Weekend
164.3600
165.1000
163.0000
164.8000
1,488,850
164.1800
165.6400
162.5800
164.6800
2,895,650
166.7800
166.9200
163.2800
164.4600
1,784,800
14 · 6-K
After market open · 10:10 ET
DIRECTOR DECLARATION ↗
168.0800
168.4400
163.5600
165.2200
1,830,750
13 · 6-K
Pre-market · 08:02 ET
KOSELUGO (SELUMETINIB) APPROVED IN THE EU ↗
166.9200
168.4200
166.4800
168.1200
3,123,950
Weekend
Weekend
166.9000
167.0400
165.8400
166.5800
1,190,200
166.3400
167.6200
166.2400
166.8000
1,074,800
166.9000
168.4200
166.5600
166.8600
1,656,650
12 · 6-K
Pre-market · 08:07 ET
TEZSPIRE APPROVED IN EU FOR CRSWNP ↗
167.6800
167.8200
166.2400
166.4400
2,808,300
169.7200
170.3600
167.5600
167.7400
2,508,050
11 · 6-K
Pre-market · 07:12 ET
US FDA APPROVES TEZSPIRE IN CRSWNP ↗
10 · 6-K
Pre-market · 06:47 ET
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO ↗
Weekend
Weekend
167.6800
170.1200
167.3000
169.3800
1,562,900
167.0400
168.8400
166.2000
167.6600
2,163,000
167.1000
170.0800
167.0600
169.6600
2,034,800
169.1600
170.3400
168.6000
170.2400
2,450,900
9 · 6-K
Pre-market · 06:05 ET
AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES ↗
168.7000
169.8400
168.1000
169.0200
2,989,950
Weekend
Weekend
171.2600
171.7600
167.7000
169.0600
7,238,150
171.8000
172.7600
169.9800
170.0800
4,546,650
172.7000
172.9600
170.3200
170.7600
3,310,550
170.8400
172.4800
170.7000
171.7400
1,746,350
8 · 6-K
Pre-market · 06:30 ET
BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL ↗
171.0800
173.1400
170.2800
170.9800
3,192,450
7 · 6-K
Pre-market · 07:18 ET
DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 ↗
Weekend
Weekend
168.6000
171.0000
167.6800
170.6200
2,934,450
166.8000
168.1000
165.7600
167.3000
2,725,600
6 · 6-K
After market open · 10:19 ET
TOTAL VOTING RIGHTS ↗
162.0800
169.2200
161.6400
168.7200
7,225,700
148.8600
153.9800
147.9200
153.4400
3,841,100
148.3800
149.3600
147.3800
148.2600
3,059,350
5 · 6-K
Pre-market · 07:05 ET
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 ↗
4 · 6-K
Pre-market · 06:59 ET
AZN HARMONISES LISTING STRUCTURE ↗
3 · 6-K
Pre-market · 06:08 ET
6-K ↗
Weekend
Weekend
147.3400
148.1200
146.6600
147.5200
2,172,700
2 · 6-K
After market open · 13:27 ET
DIRECTOR/PDMR SHAREHOLDING ↗
149.1400
149.3800
145.8000
147.0600
2,443,200
150.4000
151.3200
149.8400
150.7200
1,546,450
153.2200
153.7200
151.8000
151.9400
1,956,300
153.3400
155.7800
153.1600
155.0000
2,435,200
1 · 6-K
Pre-market · 07:46 ET
KOSELUGO RECOMMENDED FOR EU APPROVAL ↗
Weekend
Weekend
153.5800
154.5400
152.3200
152.5600
3,330,750
153.8400
154.3000
152.1600
154.1400
2,279,150
154.3800
156.1600
154.1400
155.3800
2,329,250
155.8200
156.0400
154.4800
155.1200
1,704,750
156.4400
157.0400
154.7200
156.1000
2,223,550
Weekend
Weekend
161.6400
162.3200
158.1600
159.1200
2,245,850
161.6400
162.6200
161.3600
162.2000
1,414,750
161.8200
162.2400
161.1600
161.6200
1,056,250
162.0200
162.7200
161.4800
162.4400
1,189,450
161.4600
163.2200
160.3600
163.1200
1,312,000
Weekend
Weekend
164.1000
164.8200
163.0800
163.4000
1,232,200
163.7600
164.5600
162.9600
163.5600
1,560,750
161.9000
164.3800
161.8200
164.2200
2,101,650
159.7200
161.1800
158.8600
160.3800
1,494,300
No trading
Weekend
Weekend
159.1800
160.1800
158.7400
159.8000
1,412,350
159.8600
160.3200
158.7000
159.9800
1,515,450
160.1200
160.5200
158.9400
159.8600
2,428,300
161.1400
161.1400
158.7600
160.1000
2,664,300
163.0400
163.0400
158.9800
159.3200
1,689,700
Weekend
Weekend
162.1800
163.1200
161.2200
161.9400
1,802,150
160.8000
161.9600
160.8000
160.9200
1,268,250
160.4000
162.2600
160.3600
161.0400
1,785,950
158.6600
159.6000
158.4400
159.0800
1,844,950
158.9800
159.5600
158.2000
158.2400
1,508,850
Weekend
Weekend
157.0200
158.6200
156.6000
158.3400
2,380,450
155.6400
157.1800
155.4800
156.9400
2,859,050
153.8600
156.0600
153.5800
155.8800
2,504,250
148.2200
150.7400
148.0800
150.6800
1,386,300
147.7200
148.6200
147.3200
148.1400
1,279,150
Weekend
Weekend
146.9400
147.8000
146.2200
147.1000
2,493,100
147.5800
149.2000
146.9000
149.1400
1,713,800
149.4000
150.2000
146.8400
147.2000
1,473,650
149.6800
149.9000
148.5000
148.9600
1,719,850
146.6600
149.2000
146.4400
149.1800
1,756,700
Weekend
Weekend
147.1000
148.2400
146.6800
147.9000
4,901,900
149.1800
151.2800
146.0600
146.1800
4,299,850
151.1200
153.4600
150.7200
153.1800
5,135,550
145.8400
150.0000
145.1400
147.9600
7,215,700
145.4400
146.0600
142.9800
143.6600
3,823,900
Weekend
Weekend
145.3000
145.8000
144.5400
145.3200
3,101,150
148.2600
148.7600
147.1000
147.3600
2,883,500
144.3400
146.6000
144.0000
146.0000
2,510,200
138.8400
141.0800
138.8400
140.9600
1,563,350
Announcement Events
Each title opens the filing on the SEC website. Registered users can summarise the filing and up to seven relevant exhibits linked within the same SEC submission.
94
6-K
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER (opens SEC filing in a new tab)
Pre-market · 02:01 ET
Summarise
93
6-K
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR (opens SEC filing in a new tab)
Pre-market · 06:37 ET
Summarise
92
6-K
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL (opens SEC filing in a new tab)
Pre-market · 06:17 ET
Summarise
91
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 10:10 ET
Summarise
89
6-K
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS (opens SEC filing in a new tab)
Pre-market · 06:45 ET
Summarise
88
6-K
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC (opens SEC filing in a new tab)
Pre-market · 06:05 ET
Summarise
87
6-K
TRUQAP APPROVED IN US FOR PROSTATE CANCER (opens SEC filing in a new tab)
Pre-market · 06:52 ET
Summarise
86
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 10:10 ET
Summarise
84
6-K
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER (opens SEC filing in a new tab)
Pre-market · 06:43 ET
Summarise
83
6-K
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED (opens SEC filing in a new tab)
Pre-market · 06:04 ET
Summarise
82
6-K
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC (opens SEC filing in a new tab)
Pre-market · 07:17 ET
Summarise
81
6-K
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS (opens SEC filing in a new tab)
Pre-market · 07:09 ET
Summarise
80
6-K
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU (opens SEC filing in a new tab)
Pre-market · 07:02 ET
Summarise
79
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:15 ET
Summarise
78
6-K
BAXFENDY APPROVED IN THE US FOR HYPERTENSION (opens SEC filing in a new tab)
After market open · 09:42 ET
Summarise
77
6-K
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS (opens SEC filing in a new tab)
After market open · 09:36 ET
Summarise
76
6-K
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER (opens SEC filing in a new tab)
Pre-market · 07:25 ET
Summarise
75
6-K
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES (opens SEC filing in a new tab)
After market open · 10:23 ET
Summarise
74
6-K
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER (opens SEC filing in a new tab)
Pre-market · 08:45 ET
Summarise
73
6-K
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER (opens SEC filing in a new tab)
Pre-market · 08:40 ET
Summarise
71
6-K
BREZTRI APPROVED IN THE US FOR ASTHMA (opens SEC filing in a new tab)
Pre-market · 07:31 ET
Summarise
70
6-K
SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US (opens SEC filing in a new tab)
Pre-market · 06:29 ET
Summarise
68
6-K
I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT (opens SEC filing in a new tab)
Pre-market · 06:19 ET
Summarise
67
6-K
THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD (opens SEC filing in a new tab)
Pre-market · 07:03 ET
Summarise
65
6-K
IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER (opens SEC filing in a new tab)
Pre-market · 09:27 ET
Summarise
64
6-K
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES (opens SEC filing in a new tab)
After market open · 10:30 ET
Summarise
63
6-K
EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS (opens SEC filing in a new tab)
Pre-market · 07:48 ET
Summarise
62
6-K
TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS (opens SEC filing in a new tab)
Pre-market · 08:04 ET
Summarise
61
6-K
NOTIFICATION OF ADMISSION OF SHARES (opens SEC filing in a new tab)
Pre-market · 07:59 ET
Summarise
60
6-K
IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER (opens SEC filing in a new tab)
Pre-market · 08:45 ET
Summarise
51
6-K
ASTRAZENECA PRICES A $2BN BOND OFFERING (opens SEC filing in a new tab)
Pre-market · 08:59 ET
Summarise
50
6-K
FILING OF FORM 20-F WITH SEC (opens SEC filing in a new tab)
After market open · 10:40 ET
Summarise
44
6-K
FIXED-DURATION CALQUENCE COMBO APPROVED IN US (opens SEC filing in a new tab)
Pre-market · 06:57 ET
Summarise
42
6-K
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION (opens SEC filing in a new tab)
Pre-market · 07:01 ET
Summarise
40
6-K
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER (opens SEC filing in a new tab)
Pre-market · 07:51 ET
Summarise
39
6-K
ASTRAZENECA BEGINS TRADING ON NYSE (opens SEC filing in a new tab)
Pre-market · 07:25 ET
Summarise
38
6-K
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC (opens SEC filing in a new tab)
Pre-market · 06:19 ET
Summarise
37
6-K
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 (opens SEC filing in a new tab)
Pre-market · 08:08 ET
Summarise
36
6-K
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE (opens SEC filing in a new tab)
Pre-market · 07:18 ET
Summarise
35
6-K
AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON (opens SEC filing in a new tab)
Pre-market · 06:04 ET
Summarise
32
6-K
ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC (opens SEC filing in a new tab)
Pre-market · 07:18 ET
Summarise
31
6-K
UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB (opens SEC filing in a new tab)
Pre-market · 07:02 ET
Summarise
29
6-K
SUBCUTANEOUS SAPHNELO APPROVED IN EU (opens SEC filing in a new tab)
Pre-market · 06:42 ET
Summarise
28
6-K
ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC (opens SEC filing in a new tab)
Pre-market · 06:19 ET
Summarise
26
6-K
BLOCK LISTING INTERIM REVIEW (opens SEC filing in a new tab)
After market open · 11:47 ET
Summarise
24
6-K
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER (opens SEC filing in a new tab)
Pre-market · 06:27 ET
Summarise
23
6-K
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND (opens SEC filing in a new tab)
Pre-market · 06:54 ET
Summarise
22
6-K
KOSELUGO (SELUMETINIB) APPROVED IN THE US (opens SEC filing in a new tab)
Pre-market · 08:31 ET
Summarise
20
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:12 ET
Summarise
19
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 12:15 ET
Summarise
17
6-K
RESULT OF GENERAL MEETING (opens SEC filing in a new tab)
After market open · 13:31 ET
Summarise
13
6-K
KOSELUGO (SELUMETINIB) APPROVED IN THE EU (opens SEC filing in a new tab)
Pre-market · 08:02 ET
Summarise
12
6-K
TEZSPIRE APPROVED IN EU FOR CRSWNP (opens SEC filing in a new tab)
Pre-market · 08:07 ET
Summarise
11
6-K
US FDA APPROVES TEZSPIRE IN CRSWNP (opens SEC filing in a new tab)
Pre-market · 07:12 ET
Summarise
10
6-K
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO (opens SEC filing in a new tab)
Pre-market · 06:47 ET
Summarise
9
6-K
AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES (opens SEC filing in a new tab)
Pre-market · 06:05 ET
Summarise
8
6-K
BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL (opens SEC filing in a new tab)
Pre-market · 06:30 ET
Summarise
7
6-K
DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 (opens SEC filing in a new tab)
Pre-market · 07:18 ET
Summarise
5
6-K
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 (opens SEC filing in a new tab)
Pre-market · 07:05 ET
Summarise
4
6-K
AZN HARMONISES LISTING STRUCTURE (opens SEC filing in a new tab)
Pre-market · 06:59 ET
Summarise